668 Delays in Neuroendocrine Tumor (NET) Diagnosis: U.S. Results From the First Global Net Patient Survey—A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Edward Wolin; Ron Hollander; John Leyden; Teodora Kolarova; Maia Sissons; Grace Goldstein

doi:10.1016/s0016-5085(15)30443-1

668 Delays in Neuroendocrine Tumor (NET) Diagnosis: U.S. Results From the First Global Net Patient Survey—A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Gastroenterology ◽

10.1016/s0016-5085(15)30443-1 ◽

2015 ◽

Vol 148 (4) ◽

pp. S-128

Author(s):

Edward Wolin ◽

Ron Hollander ◽

John Leyden ◽

Teodora Kolarova ◽

Maia Sissons ◽

...

Keyword(s):

Neuroendocrine Tumor ◽

Patient Survey ◽

Neuroendocrine Cancer

Download Full-text

Neuroendocrine tumor European patient experience: results from the first global NET patient survey - a collaboration between the International Neuroendocrine Cancer Alliance and Novartis

Endocrine Abstracts ◽

10.1530/endoabs.37.ep1139 ◽

2015 ◽

Cited By ~ 1

Author(s):

Kjell Oberg ◽

John Leyden ◽

Grace Goldstein ◽

Maia Sissons ◽

Teodora Kolarova

Keyword(s):

Neuroendocrine Tumor ◽

Patient Experience ◽

Patient Survey ◽

Neuroendocrine Cancer

Download Full-text

Gastrointestinal (GI) and Pancreatic Neuroendocrine Tumor (pNET) Patient Experience: US Results from the First Global NET Patient Survey—An International Neuroendocrine Cancer Alliance (INCA) and Novartis Collaboration

The American Journal of Gastroenterology ◽

10.14309/00000434-201510001-02329 ◽

2015 ◽

Vol 110 ◽

pp. S968

Author(s):

Grace Goldstein ◽

Edward Wolin ◽

Teodora Kolarova ◽

Maia Sissons ◽

John Leyden

Keyword(s):

Neuroendocrine Tumor ◽

Patient Experience ◽

Pancreatic Neuroendocrine Tumor ◽

Patient Survey ◽

Neuroendocrine Cancer

Download Full-text

Patient-reported time to diagnosis of neuroendocrine tumors (NETs) in Europe: results from the first global NET patient survey: a collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis

Endocrine Abstracts ◽

10.1530/endoabs.37.gp.28.06 ◽

2015 ◽

Cited By ~ 1

Author(s):

Marianne Pavel ◽

Teodora Kolarova ◽

Grace Goldstein ◽

John Leyden ◽

Maia Sissons

Keyword(s):

Neuroendocrine Tumors ◽

Patient Survey ◽

Neuroendocrine Cancer ◽

Patient Reported ◽

Time To Diagnosis

Download Full-text

Lung neuroendocrine tumor (NET) patient (pt)-reported experience: Results from the first global NET pt surveyA collaboration between the international neuroendocrine cancer alliance (INCA) and Novartis pharmaceuticals.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e17739 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e17739-e17739

Author(s):

Dan Granberg ◽

Maia Sissons ◽

Teodora Kolarova ◽

Grace Goldstein ◽

John Leyden

Keyword(s):

Neuroendocrine Tumor ◽

Neuroendocrine Cancer ◽

Lung Neuroendocrine Tumor

Download Full-text

Neuroendocrine tumor (NET) patient (pt) experience with disease management: Results from the first global NET pt surveyA collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e17737 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e17737-e17737

Author(s):

Simron Singh ◽

Grace Goldstein ◽

Maia Sissons ◽

Teodora Kolarova ◽

John Leyden

Keyword(s):

Disease Management ◽

Neuroendocrine Tumor ◽

Neuroendocrine Cancer

Download Full-text

Multidisciplinary team (MDT) care by neuroendocrine tumor (NET) type: Results from the first global NET patient (pt) survey—A collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e17738 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e17738-e17738

Author(s):

John Leyden ◽

Grace Goldstein ◽

Maia Sissons ◽

Teodora Kolarova ◽

Edward M. Wolin

Keyword(s):

Neuroendocrine Tumor ◽

Multidisciplinary Team ◽

Neuroendocrine Cancer

Download Full-text

Quantifying the Net Patient Experience Through the First Global Net Patient Survey: a Collaboration Between the International Neuroendocrine Cancer Alliance and Novartis

Annals of Oncology ◽

10.1093/annonc/mdu345.33 ◽

2014 ◽

Vol 25 ◽

pp. iv405 ◽

Cited By ~ 1

Author(s):

T. Kolarova ◽

M. Sissons ◽

J. Leyden

Keyword(s):

Patient Experience ◽

Patient Survey ◽

Neuroendocrine Cancer

Download Full-text

Interferon γ mediated induction of apoptosis in primary human neuroendocrine tumor cells

Gastroenterology ◽

10.1016/s0016-5085(01)82527-0 ◽

2001 ◽

Vol 120 (5) ◽

pp. A509-A509

Author(s):

A DROST ◽

J KEHRBERGER ◽

U PLOECKINGER ◽

B WIEDENMANN ◽

S ROSEWICZ ◽

...

Keyword(s):

Neuroendocrine Tumor ◽

Tumor Cells ◽

Interferon Γ ◽

Induction Of Apoptosis

Download Full-text

572 ASSOCIATION BETWEEN SOMATOSTATIN ANALOGUE TREATMENT AND DIABETES MELLITUS IN GI NEUROENDOCRINE TUMOR PATIENTS: A STUDY OF 4,664 SEER-MEDICARE DATABASE PATIENTS

Gastroenterology ◽

10.1016/s0016-5085(20)30978-1 ◽

2020 ◽

Vol 158 (6) ◽

pp. S-119-S-120

Author(s):

Katherine Ni ◽

Kiwoon Joshua Baeg ◽

Juan P. Wisnivesky ◽

Michelle Kim

Keyword(s):

Diabetes Mellitus ◽

Neuroendocrine Tumor ◽

Somatostatin Analogue ◽

Tumor Patients ◽

Medicare Database

Download Full-text

Abstract #805732: Duodenal Neuroendocrine Tumor with Liver Metastasis with High Circulating Levels of Calcitonin and Negative Octreoscan and Normal Chromogranin-A

Endocrine Practice ◽

10.1016/s1530-891x(20)39641-5 ◽

2020 ◽

Vol 26 ◽

pp. 216-217

Author(s):

Jose Paz-Ibarra

Keyword(s):

Liver Metastasis ◽

Neuroendocrine Tumor ◽

Chromogranin A ◽

Circulating Levels

Download Full-text

668 Delays in Neuroendocrine Tumor (NET) Diagnosis: U.S. Results From the First Global Net Patient Survey—A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Neuroendocrine tumor European patient experience: results from the first global NET patient survey - a collaboration between the International Neuroendocrine Cancer Alliance and Novartis

Gastrointestinal (GI) and Pancreatic Neuroendocrine Tumor (pNET) Patient Experience: US Results from the First Global NET Patient Survey—An International Neuroendocrine Cancer Alliance (INCA) and Novartis Collaboration

Patient-reported time to diagnosis of neuroendocrine tumors (NETs) in Europe: results from the first global NET patient survey: a collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis

Lung neuroendocrine tumor (NET) patient (pt)-reported experience: Results from the first global NET pt surveyA collaboration between the international neuroendocrine cancer alliance (INCA) and Novartis pharmaceuticals.

Neuroendocrine tumor (NET) patient (pt) experience with disease management: Results from the first global NET pt surveyA collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis.

Multidisciplinary team (MDT) care by neuroendocrine tumor (NET) type: Results from the first global NET patient (pt) survey—A collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis.

Quantifying the Net Patient Experience Through the First Global Net Patient Survey: a Collaboration Between the International Neuroendocrine Cancer Alliance and Novartis

Interferon γ mediated induction of apoptosis in primary human neuroendocrine tumor cells

572 ASSOCIATION BETWEEN SOMATOSTATIN ANALOGUE TREATMENT AND DIABETES MELLITUS IN GI NEUROENDOCRINE TUMOR PATIENTS: A STUDY OF 4,664 SEER-MEDICARE DATABASE PATIENTS

Abstract #805732: Duodenal Neuroendocrine Tumor with Liver Metastasis with High Circulating Levels of Calcitonin and Negative Octreoscan and Normal Chromogranin-A

Lung neuroendocrine tumor (NET) patient (pt)-reported experience: Results from the first global NET pt surveyA collaboration between the international neuroendocrine cancer alliance (INCA) and Novartis pharmaceuticals.

Neuroendocrine tumor (NET) patient (pt) experience with disease management: Results from the first global NET pt surveyA collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis.